Trials / Completed
CompletedNCT00881634
To Demonstrate the Relative Bioavailability of Cetirizine Hydrochloride/Pseudoephedrine Hydrochloride 5 mg/120 mg Extended Release (ER) Tablets Under Fed Conditions
A Single-Dose Comparative Bioavailability Study of Two Formulations of Cetirizine Hydrochloride/Pseudoephedrine Hydrochloride 5 mg/120 mg Extended Release Tablets Under Fed Conditions
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Sandoz · Industry
- Sex
- All
- Age
- 20 Years – 53 Years
- Healthy volunteers
- Accepted
Summary
To demonstrate the relative bioavailability of Cetirizine Hydrochloride/Pseudoephedrine Hydrochloride 5 mg/120 mg ER tablets under fed conditions.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cetirizine HCl/Pseudoephedrine HCl 5 mg/120 mg Tablets (Sandoz, USA) | |
| DRUG | Zyrtec-D 12 Hour 5 mg/120 mg Extended Release Tablets (Pfizer, USA) |
Timeline
- Start date
- 2005-06-01
- Primary completion
- 2005-07-01
- Completion
- 2005-07-01
- First posted
- 2009-04-15
- Last updated
- 2017-03-28
Source: ClinicalTrials.gov record NCT00881634. Inclusion in this directory is not an endorsement.